四价ACWY群脑膜炎球菌疫苗及靶向B群疫苗接种对法国影响的模型研究
研究使用年龄结构房室模型模拟法国B、W、Y群脑膜炎球菌携带与侵袭性脑膜炎球菌病(IMD)动态,评估引入ACWY群或B群疫苗接种对IMD病例的影响。模型假设下,ACWY群疫苗最佳策略为针对婴儿和青少年并补充至25岁的补种活动,20年后可减少93%的IMD-W病例;B群疫苗接种在所有情景下对IMD-B病例的总体降幅均低于20%。该评估为法国国家卫生管理局的脑膜炎球菌疫苗接种建议提供了依据。
要点
- ACWY群疫苗针对婴儿和青少年并补充至25岁补种,模型预测20年后减少93%的IMD-W病例。
- 接种活动开始后5至10年,仅针对青少年可能达到相似结果,兼顾公共卫生效益与成本。
- B群疫苗接种在所有研究情景中对IMD-B病例的总体降幅均低于20%,即使长期亦如此。
核心结论
- 在模型假设下,ACWY群疫苗针对婴儿和青少年并补充至25岁补种可大幅减少IMD-W病例,而B群疫苗在所有情景下对IMD-B病例的降幅有限。
研究设计与样本
- 使用年龄结构房室模型描述B、W、Y群脑膜炎球菌携带与IMD病例动态,测试ACWY群和B群疫苗在不同年龄接种的多种情景。
主要发现
- ACWY群疫苗最佳策略为针对婴儿和青少年并补充至25岁补种,20年后可减少93%的IMD-W病例。
- 接种活动开始后5至10年,仅针对青少年可能达到相似结果。
- B群疫苗接种在所有研究情景下IMD-B病例总体降幅均低于20%,即使长期亦如此。
临床怎么用
- 该评估为法国技术疫苗接种委员会关于脑膜炎球菌疫苗接种策略的讨论提供了信息,并被纳入法国国家卫生管理局的建议且获卫生部认可。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive meningococcal disease (IMD) represents a significant global health burden, with high fatality rate and substantial risk of lifelong sequelae. Most cases worldwide are caused by six serogroups (A, B, C, W, X, and Y). Effective vaccines are available to prevent disease caused by serogroups A, B, C, W, and Y. In France, approximately 500 IMD cases occur each year. Since the introduction of mandatory vaccination against serogroup C, the majority of IMD now involve serogroups B, W, and Y. Given these changes in the epidemiology of IMD, French National Authority for Health decided to reconsider its recommendations on meningococcal vaccines. Using an age structured compartmental model describing meningococcal carriage and IMD cases dynamics of serogroups B, W, and Y, we evaluated the expected impact of introducing vaccination against serogroup ACWY or serogroup B on IMD cases in France. Several scenarios were tested to determine the benefits of vaccination at different ages for both ACWY and serogroup B vaccination, in terms of burden reduction and number of vaccinations needed. Under our modelling assumptions we find that for ACWY vaccination the optimal strategy is to target infants and adolescents, supplemented by a catch-up campaign up to the age of 25, which could reduce IMD-W cases by 93 % after 20 years. Five to ten years from the start of the vaccination campaign, focusing only on adolescents may achieve similar outcomes, balancing public health benefits while minimizing costs. For serogroup B vaccination, results showed a limited impact, with the overall reduction of IMD-B cases remaining below 20 % in all studied scenarios, even in the long term. This evaluation informed the discussions of the Technical Vaccination Committee regarding the vaccination strategy for meningococcus and was included in the recommendations of the French National Authority for Health, endorsed by the Ministry of Health.
引用
- Bosetti P, Peckeu-Abboud L, Andrianasolo RM, et al. Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France. Vaccine. 2025. PMID: 41129884. doi:10.1016/j.vaccine.2025.127871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。